salicylates and benoxaprofen

Rheumatoid Arthritis (RA) is a progressive disease of unknown aetiology which may be caused by faulty immune mechanisms. Early diagnosis and correct treatment can be extremely effective. Fast and lasting results can only be obtained by an appropriate combination of NSAID and DMARD drugs which both reduce subjective symptoms and halt the progression of the disease.

Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Arthritis, Rheumatoid; Azathioprine; Gold; Humans; Indomethacin; Levamisole; Penicillamine; Phenylbutazone; Propionates; Salicylates; Sulindac; Tolmetin

Non-steroidal anti-inflammatory drugs are theoretically contra-indicated in the haemophilias but might be useful for those patients with chronic arthritic pain, as long-term strong analgesics are also undesirable. We carried out studies of platelet function and coagulation in 8 normal controls and 7 haemophiliacs while they were taking sequentially benoxaprofen and salsalate. No significant alterations in platelet function, bleeding time or coagulation occurred with either drug. In a subsequent double-blind controlled clinical trial using ibuprofen and placebo 8 of 9 patients had a significant reduction in pain score whilst using ibuprofen without significant change in the frequency of bleeds or the amount of concentrate used. Laboratory measures of coagulation also failed to reveal any adverse effect of the active drug. Non-steroidal anti-inflammatory drugs may be beneficial and may be used with caution in haemophilia.

Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis; Blood Platelets; Clinical Trials as Topic; Hemophilia A; Humans; Ibuprofen; Middle Aged; Propionates; Salicylates

A total of 30 patients participated in a double-blind crossover trial to compare the efficacy and safety of benoxaprofen with naproxen in the treatment of osteoarthritis. Benoxaprofen, 600 mg administered once daily, was as effective as naproxen, 250 mg administered twice daily. Adverse reactions were mostly mild to moderate in severity and the incidence of the reactions was similar for the 2 study drugs. The advantage of the once-a-day dose regimen of benoxaprofen is discussed.

Topics: Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents; Benzoxazoles; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Naproxen; Osteoarthritis; Patient Compliance; Propionates; Salicylates; Time Factors

In vitro assays of human neutrophil phagocytosis, adherence, enzyme release, and response to chemotactic factors were utilized to determine the effects of benoxaprofen on these cells. At concentrations of 30 and 300 micrograms/ml benoxaprofen partially inhibited phagocytosis without affecting adherence. High concentrations (300 micrograms/ml) of benoxaprofen, but not aspirin or gold, enhanced the release of the granular enzymes beta-glucuronidase and lysozyme, but not the release of the cytoplasmic enzyme lactic dehydrogenase from both resting and phagocytosing neutrophils. High concentrations (300 micrograms/ml) of benoxaprofen also inhibited the response of neutrophils to chemotactic factors as determined by both the leading front and leukotactic index methods. These unique in vitro effects of this antiinflammatory agent are compatible with recent clinical reports concerning its efficacy and toxicity.

Topics: Cell Adhesion; Chemotaxis; Enzyme Induction; Glucuronidase; Humans; L-Lactate Dehydrogenase; Muramidase; Neutrophils; Phagocytosis; Propionates; Salicylates